TEVA
Teva Pharmaceutical Industries Limited
Price Chart
Latest Quote
$32.03
-0.19 (-0.59%)
Current Price
| Previous Close | $32.22 |
| Open | $32.13 |
| Day High | $32.69 |
| Day Low | $31.95 |
| Volume | 3,056,065 |
Stock Information
| Shares Outstanding | 1.16B |
| Total Debt | $16.92B |
| Cash Equivalents | $3.74B |
| Revenue | $17.35B |
| Net Income | $1.56B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $37.30B |
| P/E Ratio | 24.08 |
| EPS (TTM) | $1.33 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $50.48B |
| Sales | $17.35B |
| Income | $1.56B |
| Book/sh | $7.07 |
| Cash/sh | $3.21 |
| Employees | 31K |
Financial Ratios
| Quick Ratio | 0.53 |
| Current Ratio | 1.01 |
| Debt/Eq | 205.60 |
| EPS Growth TTM | 72.40% |
Returns & Margins
| ROA | 6.38% |
| ROE | 21.60% |
| Gross Margin | 52.06% |
| Operating Margin | 19.16% |
| Profit Margin | 9.02% |
Ownership
| Insider Ownership | 0.00% |
| Institutional Ownership | 62.40% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.40 |
| PEG | 0.90 |
| P/S | 2.15 |
| P/B | 4.53 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $40.90 |
Technical Indicators
| SMA20 | $33.11 |
| SMA50 | $33.93 |
| SMA200 | $30.11 |
| RSI | 42.18 |
| ATR | 0.9550 |
| Shares Float | 1.08B |
| Short Float | 2.77% |
| Short Ratio | 5.16 |
| Volatility | 0.86 |
| Rel Volume | 0.65 |
Performance History
| Week | -2.79% |
| Month | -2.67% |
| Quarter | +2.46% |
| 6 Months | -1.87% |
| YTD | +3.49% |
| Year | +100.06% |
| 3 Years | +296.90% |
| 5 Years | +244.41% |
| 10 Years | -37.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $32.03 | 3,612,300 |
| 2026-07-16 | $32.22 | 4,453,500 |
| 2026-07-15 | $31.56 | 5,519,700 |
| 2026-07-14 | $31.82 | 3,452,200 |
| 2026-07-13 | $32.18 | 4,231,200 |
| 2026-07-10 | $32.95 | 6,638,100 |
| 2026-07-09 | $33.10 | 5,112,800 |
| 2026-07-08 | $33.24 | 6,623,500 |
| 2026-07-07 | $34.65 | 5,566,000 |
| 2026-07-06 | $35.29 | 4,116,800 |
| 2026-07-02 | $34.64 | 4,814,800 |
| 2026-07-01 | $33.44 | 4,241,100 |
| 2026-06-30 | $33.88 | 5,396,100 |
| 2026-06-29 | $33.31 | 3,271,600 |
| 2026-06-26 | $33.21 | 4,703,600 |
| 2026-06-25 | $33.62 | 7,447,600 |
| 2026-06-24 | $34.22 | 7,249,300 |
| 2026-06-23 | $33.21 | 5,567,200 |
| 2026-06-22 | $32.20 | 6,111,100 |
| 2026-06-18 | $31.48 | 12,241,500 |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
đ° Latest News
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
Zacks âĸ 2026-07-15T14:50:00Z
Teva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progress
Simply Wall St. âĸ 2026-07-14T04:31:43Z
Teva (TEVA) Stock Looks Discounted On Cash Flow Yet Fair On Earnings
Simply Wall St. âĸ 2026-07-13T15:11:09Z
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
Zacks âĸ 2026-07-13T14:43:00Z
Teva (TEVA) Reports Promising Vitiligo Trial Results And Moves Anti IL 15 Drug Forward
Simply Wall St. âĸ 2026-07-13T12:07:44Z
Teva Pharmaceutical Industriesâ Anti-IL-15 Antibody Shows Promise in Vitiligo Study
MarketBeat âĸ 2026-07-12T22:02:03Z
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
MarketBeat âĸ 2026-07-12T21:02:01Z
Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
Pharmaceutical Technology âĸ 2026-07-10T10:31:18Z
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-07-09T16:32:04Z
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Zacks âĸ 2026-07-09T13:25:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $8,320,000,000 | $8,481,000,000 | $8,200,000,000 | $7,952,000,000 |
| Cost Of Revenue | $8,320,000,000 | $8,481,000,000 | $8,200,000,000 | $7,952,000,000 |
| Total Revenue | $17,257,000,000 | $16,544,000,000 | $15,845,000,000 | $14,925,000,000 |
| Operating Revenue | $16,834,000,000 | $15,799,000,000 | $15,275,000,000 | $14,497,000,000 |
| Expenses | ||||
| Interest Expense | $916,000,000 | $1,002,000,000 | $1,029,000,000 | $930,000,000 |
| Total Expenses | $13,306,000,000 | $13,181,000,000 | $12,651,000,000 | $12,235,000,000 |
| Other Income Expense | $-1,742,000,000 | $-3,597,000,000 | $-2,723,000,000 | $-4,859,000,000 |
| Other Non Operating Income Expenses | $1,000,000 | $10,000,000 | $-9,000,000 | $-26,000,000 |
| Net Non Operating Interest Income Expense | $-985,000,000 | $-1,050,000,000 | $-1,095,000,000 | $-991,000,000 |
| Total Other Finance Cost | $69,000,000 | $48,000,000 | $66,000,000 | $61,000,000 |
| Interest Expense Non Operating | $916,000,000 | $1,002,000,000 | $1,029,000,000 | $930,000,000 |
| Operating Expense | $4,986,000,000 | $4,700,000,000 | $4,451,000,000 | $4,283,000,000 |
| Selling And Marketing Expense | $2,686,000,000 | $2,541,000,000 | $2,336,000,000 | $2,265,000,000 |
| General And Administrative Expense | $1,287,000,000 | $1,161,000,000 | $1,162,000,000 | $1,180,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,410,000,000 | $-1,639,000,000 | $-559,000,000 | $-2,446,000,000 |
| Net Interest Income | $-985,000,000 | $-1,050,000,000 | $-1,095,000,000 | $-991,000,000 |
| Normalized Income | $2,752,110,000 | $1,138,390,000 | $2,127,860,000 | $1,420,400,000 |
| Net Income From Continuing And Discontinued Operation | $1,410,000,000 | $-1,639,000,000 | $-559,000,000 | $-2,446,000,000 |
| Total Operating Income As Reported | $2,157,000,000 | $-303,000,000 | $433,000,000 | $-2,197,000,000 |
| Net Income Common Stockholders | $1,410,000,000 | $-1,639,000,000 | $-559,000,000 | $-2,446,000,000 |
| Net Income | $1,410,000,000 | $-1,639,000,000 | $-559,000,000 | $-2,446,000,000 |
| Net Income Including Noncontrolling Interests | $1,418,000,000 | $-1,959,000,000 | $-615,000,000 | $-2,499,000,000 |
| Net Income Continuous Operations | $1,418,000,000 | $-1,959,000,000 | $-615,000,000 | $-2,499,000,000 |
| Earnings From Equity Interest Net Of Tax | $15,000,000 | $1,000,000 | $2,000,000 | $21,000,000 |
| Pretax Income | $1,223,000,000 | $-1,284,000,000 | $-624,000,000 | $-3,163,000,000 |
| Special Income Charges | $-1,794,000,000 | $-3,676,000,000 | $-2,752,000,000 | $-4,859,000,000 |
| Operating Income | $3,952,000,000 | $3,364,000,000 | $3,194,000,000 | $2,690,000,000 |
| Gross Profit | $8,938,000,000 | $8,064,000,000 | $7,645,000,000 | $6,973,000,000 |
| Per Share | ||||
| Diluted EPS | $1.21 | $-1.45 | $-0.50 | $-2.12 |
| Basic EPS | $1.23 | $-1.45 | $-0.50 | $-2.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $-400,890,000 | $-829,610,000 | $-27,140,000 | $-966,600,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $4,884,000,000 | $4,384,000,000 | $4,272,000,000 | $3,908,000,000 |
| Total Unusual Items | $-1,743,000,000 | $-3,607,000,000 | $-2,714,000,000 | $-4,833,000,000 |
| Total Unusual Items Excluding Goodwill | $-1,743,000,000 | $-3,607,000,000 | $-2,714,000,000 | $-4,833,000,000 |
| Reconciled Depreciation | $1,002,000,000 | $1,059,000,000 | $1,153,000,000 | $1,308,000,000 |
| EBITDA (Bullshit earnings) | $3,141,000,000 | $777,000,000 | $1,558,000,000 | $-925,000,000 |
| EBIT | $2,139,000,000 | $-282,000,000 | $405,000,000 | $-2,233,000,000 |
| Diluted Average Shares | $1,163,000,000 | $1,131,000,000 | $1,119,000,000 | $1,110,000,000 |
| Basic Average Shares | $1,145,000,000 | $1,131,000,000 | $1,119,000,000 | $1,110,000,000 |
| Diluted NI Availto Com Stockholders | $1,410,000,000 | $-1,639,000,000 | $-559,000,000 | $-2,446,000,000 |
| Minority Interests | $-7,000,000 | $320,000,000 | $56,000,000 | $53,000,000 |
| Tax Provision | $-180,000,000 | $676,000,000 | $-7,000,000 | $-643,000,000 |
| Gain On Sale Of Ppe | $2,000,000 | $2,000,000 | $25,000,000 | $18,000,000 |
| Gain On Sale Of Business | $-22,000,000 | $15,000,000 | $3,000,000 | $46,000,000 |
| Other Special Charges | $467,000,000 | $761,000,000 | $1,043,000,000 | $2,069,000,000 |
| Impairment Of Capital Assets | $1,028,000,000 | $2,555,000,000 | $1,078,000,000 | $2,447,000,000 |
| Restructuring And Mergern Acquisition | $279,000,000 | $377,000,000 | $659,000,000 | $407,000,000 |
| Gain On Sale Of Security | $51,000,000 | $69,000,000 | $38,000,000 | $26,000,000 |
| Research And Development | $1,013,000,000 | $998,000,000 | $953,000,000 | $838,000,000 |
| Selling General And Administration | $3,973,000,000 | $3,702,000,000 | $3,498,000,000 | $3,445,000,000 |
| Other Gand A | $1,287,000,000 | $1,161,000,000 | $1,162,000,000 | $1,180,000,000 |
Fetched: 2026-07-03
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-11,871,000,000 | $-14,192,000,000 | $-15,058,000,000 | $-16,099,000,000 |
| Total Assets | $40,748,000,000 | $39,326,000,000 | $43,479,000,000 | $44,011,000,000 |
| Total Non Current Assets | $26,802,000,000 | $26,774,000,000 | $30,993,000,000 | $31,960,000,000 |
| Other Non Current Assets | $405,000,000 | $462,000,000 | $470,000,000 | $441,000,000 |
| Non Current Deferred Assets | $2,191,000,000 | $1,799,000,000 | $1,812,000,000 | $1,458,000,000 |
| Non Current Deferred Taxes Assets | $2,191,000,000 | $1,799,000,000 | $1,812,000,000 | $1,458,000,000 |
| Goodwill And Other Intangible Assets | $19,781,000,000 | $19,565,000,000 | $22,564,000,000 | $23,903,000,000 |
| Other Intangible Assets | $3,781,000,000 | $4,418,000,000 | $5,387,000,000 | $6,270,000,000 |
| Current Assets | $13,946,000,000 | $12,552,000,000 | $12,485,000,000 | $12,051,000,000 |
| Other Current Assets | $538,000,000 | $409,000,000 | $505,000,000 | $549,000,000 |
| Assets Held For Sale Current | $1,842,000,000 | $1,771,000,000 | $70,000,000 | $10,000,000 |
| Prepaid Assets | $1,122,000,000 | $1,006,000,000 | $1,255,000,000 | $1,162,000,000 |
| Inventory | $3,179,000,000 | $3,007,000,000 | $4,021,000,000 | $3,833,000,000 |
| Receivables | $3,709,000,000 | $3,059,000,000 | $3,408,000,000 | $3,696,000,000 |
| Accounts Receivable | $3,709,000,000 | $3,059,000,000 | $3,408,000,000 | $3,696,000,000 |
| Allowance For Doubtful Accounts Receivable | $-81,000,000 | $-78,000,000 | $-95,000,000 | $-91,000,000 |
| Gross Accounts Receivable | $3,790,000,000 | $3,137,000,000 | $3,503,000,000 | $3,787,000,000 |
| Cash Cash Equivalents And Short Term Investments | $3,556,000,000 | $3,300,000,000 | $3,226,000,000 | $2,801,000,000 |
| Cash And Cash Equivalents | $3,556,000,000 | $3,300,000,000 | $3,226,000,000 | $2,801,000,000 |
| Cash Equivalents | $2,678,000,000 | $2,005,000,000 | $1,704,000,000 | $1,222,000,000 |
| Cash Financial | $878,000,000 | $1,295,000,000 | $1,522,000,000 | $1,579,000,000 |
| Debt | ||||
| Net Debt | $13,250,000,000 | $14,483,000,000 | $16,607,000,000 | $18,411,000,000 |
| Total Debt | $17,094,000,000 | $18,079,000,000 | $20,153,000,000 | $21,561,000,000 |
| Long Term Debt And Capital Lease Obligation | $15,274,000,000 | $16,298,000,000 | $18,481,000,000 | $19,452,000,000 |
| Long Term Debt | $14,986,000,000 | $16,002,000,000 | $18,161,000,000 | $19,103,000,000 |
| Current Debt And Capital Lease Obligation | $1,820,000,000 | $1,781,000,000 | $1,672,000,000 | $2,109,000,000 |
| Current Debt | $1,820,000,000 | $1,781,000,000 | $1,672,000,000 | $2,109,000,000 |
| Other Current Borrowings | $1,820,000,000 | $1,781,000,000 | $1,672,000,000 | $2,109,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $32,834,000,000 | $33,606,000,000 | $35,353,000,000 | $35,413,000,000 |
| Total Non Current Liabilities Net Minority Interest | $19,378,000,000 | $20,810,000,000 | $23,106,000,000 | $23,944,000,000 |
| Other Non Current Liabilities | $3,808,000,000 | $4,029,000,000 | $4,019,000,000 | $3,944,000,000 |
| Non Current Deferred Liabilities | $296,000,000 | $483,000,000 | $606,000,000 | $548,000,000 |
| Non Current Deferred Taxes Liabilities | $296,000,000 | $483,000,000 | $606,000,000 | $548,000,000 |
| Current Liabilities | $13,456,000,000 | $12,796,000,000 | $12,247,000,000 | $11,469,000,000 |
| Other Current Liabilities | $1,536,000,000 | $1,718,000,000 | $1,056,000,000 | $1,006,000,000 |
| Payables And Accrued Expenses | $5,218,000,000 | $4,995,000,000 | $5,373,000,000 | $4,038,000,000 |
| Payables | $2,531,000,000 | $2,203,000,000 | $2,602,000,000 | $1,887,000,000 |
| Accounts Payable | $2,531,000,000 | $2,203,000,000 | $2,602,000,000 | $1,887,000,000 |
| Tradeand Other Payables Non Current | - | - | - | $3,847,000,000 |
| Equity | ||||
| Common Stock Equity | $7,910,000,000 | $5,373,000,000 | $7,506,000,000 | $7,804,000,000 |
| Total Equity Gross Minority Interest | $7,914,000,000 | $5,720,000,000 | $8,126,000,000 | $8,598,000,000 |
| Stockholders Equity | $7,910,000,000 | $5,373,000,000 | $7,506,000,000 | $7,804,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,391,000,000 | $-3,148,000,000 | $-2,697,000,000 | $-2,838,000,000 |
| Other Equity Adjustments | $-2,391,000,000 | $-3,148,000,000 | $-2,697,000,000 | $-2,838,000,000 |
| Retained Earnings | $-13,762,000,000 | $-15,173,000,000 | $-13,534,000,000 | $-12,975,000,000 |
| Other Equity Interest | - | - | $1,000,000 | - |
| Other | ||||
| Treasury Shares Number | $106,555,787 | $107,000,000 | $106,000,000 | $106,000,000 |
| Ordinary Shares Number | $1,149,812,898 | $1,133,838,689 | $1,121,094,011 | $1,110,899,783 |
| Share Issued | $1,256,368,685 | $1,240,838,689 | $1,227,094,011 | $1,216,899,783 |
| Tangible Book Value | $-11,871,000,000 | $-14,192,000,000 | $-15,058,000,000 | $-16,099,000,000 |
| Invested Capital | $24,716,000,000 | $23,156,000,000 | $27,339,000,000 | $29,016,000,000 |
| Working Capital | $490,000,000 | $-244,000,000 | $238,000,000 | $582,000,000 |
| Capital Lease Obligations | $288,000,000 | $296,000,000 | $320,000,000 | $349,000,000 |
| Total Capitalization | $22,896,000,000 | $21,375,000,000 | $25,667,000,000 | $26,907,000,000 |
| Minority Interest | $4,000,000 | $347,000,000 | $620,000,000 | $794,000,000 |
| Treasury Stock | $4,128,000,000 | $4,128,000,000 | $4,128,000,000 | $4,128,000,000 |
| Additional Paid In Capital | $28,133,000,000 | $27,764,000,000 | $27,807,000,000 | $27,688,000,000 |
| Capital Stock | $58,000,000 | $58,000,000 | $57,000,000 | $57,000,000 |
| Common Stock | $58,000,000 | $58,000,000 | $57,000,000 | $57,000,000 |
| Long Term Capital Lease Obligation | $288,000,000 | $296,000,000 | $320,000,000 | $349,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $739,000,000 | $624,000,000 | $611,000,000 | $566,000,000 |
| Current Provisions | $4,143,000,000 | $3,678,000,000 | $3,535,000,000 | $3,750,000,000 |
| Current Accrued Expenses | $2,687,000,000 | $2,792,000,000 | $2,771,000,000 | $2,151,000,000 |
| Goodwill | $16,000,000,000 | $15,147,000,000 | $17,177,000,000 | $17,633,000,000 |
| Net PPE | $4,425,000,000 | $4,948,000,000 | $6,147,000,000 | $6,158,000,000 |
| Accumulated Depreciation | $-4,728,000,000 | $-4,410,000,000 | $-5,637,000,000 | $-5,518,000,000 |
| Gross PPE | $9,153,000,000 | $9,358,000,000 | $11,784,000,000 | $11,676,000,000 |
| Construction In Progress | $377,000,000 | $1,330,000,000 | $1,427,000,000 | $1,199,000,000 |
| Other Properties | $345,000,000 | $367,000,000 | $397,000,000 | $419,000,000 |
| Machinery Furniture Equipment | $5,846,000,000 | $5,480,000,000 | $7,226,000,000 | $7,349,000,000 |
| Buildings And Improvements | $2,327,000,000 | $1,968,000,000 | $2,488,000,000 | $2,463,000,000 |
| Land And Improvements | $258,000,000 | $213,000,000 | $246,000,000 | $246,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,904,000,000 | $1,783,000,000 | $2,346,000,000 | $1,987,000,000 |
| Work In Process | $364,000,000 | $353,000,000 | $500,000,000 | $555,000,000 |
| Raw Materials | $911,000,000 | $870,000,000 | $1,176,000,000 | $1,291,000,000 |
| Other Inventories | - | $1,000,000 | $-1,000,000 | - |
Fetched: 2026-07-03
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,148,000,000 | $749,000,000 | $842,000,000 | $1,042,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,649,000,000 | $1,247,000,000 | $1,368,000,000 | $1,590,000,000 |
| Cash Flow From Continuing Operating Activities | $1,649,000,000 | $1,247,000,000 | $1,368,000,000 | $1,590,000,000 |
| Operating Gains Losses | - | $-22,000,000 | $-41,000,000 | $10,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-501,000,000 | $-498,000,000 | $-526,000,000 | $-548,000,000 |
| Investing Cash Flow | $737,000,000 | $792,000,000 | $968,000,000 | $656,000,000 |
| Cash Flow From Continuing Investing Activities | $737,000,000 | $792,000,000 | $968,000,000 | $656,000,000 |
| Net Other Investing Changes | $5,000,000 | $2,000,000 | $-5,000,000 | - |
| Financing Activities | ||||
| Financing Cash Flow | $-2,151,000,000 | $-1,791,000,000 | $-1,913,000,000 | $-1,487,000,000 |
| Cash Flow From Continuing Financing Activities | $-2,151,000,000 | $-1,791,000,000 | $-1,913,000,000 | $-1,487,000,000 |
| Net Other Financing Charges | $-337,000,000 | $-150,000,000 | $-212,000,000 | $-118,000,000 |
| Other | ||||
| Repayment Of Debt | $-4,112,000,000 | $-1,641,000,000 | $-4,852,000,000 | $-1,369,000,000 |
| Issuance Of Debt | $2,298,000,000 | $0 | $3,151,000,000 | $0 |
| Interest Paid Supplemental Data | $950,000,000 | $1,004,000,000 | $1,078,000,000 | $948,000,000 |
| End Cash Position | $3,556,000,000 | $3,300,000,000 | $3,227,000,000 | $2,834,000,000 |
| Beginning Cash Position | $3,300,000,000 | $3,227,000,000 | $2,834,000,000 | $2,198,000,000 |
| Effect Of Exchange Rate Changes | $21,000,000 | $-174,000,000 | $-30,000,000 | $-123,000,000 |
| Changes In Cash | $235,000,000 | $247,000,000 | $423,000,000 | $759,000,000 |
| Net Issuance Payments Of Debt | $-1,814,000,000 | $-1,641,000,000 | $-1,701,000,000 | $-1,369,000,000 |
| Net Short Term Debt Issuance | $0 | $0 | $0 | $0 |
| Short Term Debt Payments | $0 | $0 | $-700,000,000 | $0 |
| Short Term Debt Issuance | $0 | $0 | $700,000,000 | $0 |
| Net Long Term Debt Issuance | $-1,814,000,000 | $-1,641,000,000 | $-1,701,000,000 | $-1,369,000,000 |
| Long Term Debt Payments | $-4,112,000,000 | $-1,641,000,000 | $-4,152,000,000 | $-1,369,000,000 |
| Long Term Debt Issuance | $2,298,000,000 | $0 | $2,451,000,000 | $0 |
| Interest Received Cfi | $1,214,000,000 | $1,291,000,000 | $1,477,000,000 | $1,140,000,000 |
| Net Investment Purchase And Sale | $-15,000,000 | $-31,000,000 | $-46,000,000 | $3,000,000 |
| Sale Of Investment | $42,000,000 | $40,000,000 | $0 | $4,000,000 |
| Purchase Of Investment | $-57,000,000 | $-71,000,000 | $-46,000,000 | $-1,000,000 |
| Net Business Purchase And Sale | $34,000,000 | $28,000,000 | $68,000,000 | $61,000,000 |
| Sale Of Business | $34,000,000 | $43,000,000 | $68,000,000 | $68,000,000 |
| Purchase Of Business | $0 | $-15,000,000 | $0 | $-7,000,000 |
| Net PPE Purchase And Sale | $-501,000,000 | $-498,000,000 | $-526,000,000 | $-548,000,000 |
| Purchase Of PPE | $-501,000,000 | $-498,000,000 | $-526,000,000 | $-548,000,000 |
| Change In Working Capital | $-1,366,000,000 | $-435,000,000 | $-72,000,000 | $1,355,000,000 |
| Change In Other Current Assets | $-1,330,000,000 | $-1,104,000,000 | $-1,525,000,000 | $-828,000,000 |
| Change In Payables And Accrued Expense | $-15,000,000 | $258,000,000 | $1,588,000,000 | $2,012,000,000 |
| Change In Payable | $-15,000,000 | $258,000,000 | $1,588,000,000 | $2,012,000,000 |
| Change In Account Payable | $-15,000,000 | $258,000,000 | $1,588,000,000 | $2,012,000,000 |
| Change In Inventory | $152,000,000 | $166,000,000 | $-147,000,000 | $-163,000,000 |
| Change In Receivables | $-173,000,000 | $245,000,000 | $12,000,000 | $334,000,000 |
| Changes In Account Receivables | $-173,000,000 | $245,000,000 | $12,000,000 | $334,000,000 |
| Other Non Cash Items | $81,000,000 | $560,000,000 | $61,000,000 | $-91,000,000 |
| Stock Based Compensation | $157,000,000 | $123,000,000 | $121,000,000 | $124,000,000 |
| Asset Impairment Charge | $1,028,000,000 | $2,555,000,000 | $1,078,000,000 | $2,447,000,000 |
| Deferred Tax | $-671,000,000 | $-634,000,000 | $-317,000,000 | $-1,064,000,000 |
| Deferred Income Tax | $-671,000,000 | $-634,000,000 | $-317,000,000 | $-1,064,000,000 |
| Depreciation Amortization Depletion | $1,002,000,000 | $1,059,000,000 | $1,153,000,000 | $1,308,000,000 |
| Depreciation And Amortization | $1,002,000,000 | $1,059,000,000 | $1,153,000,000 | $1,308,000,000 |
| Amortization Cash Flow | $581,000,000 | $588,000,000 | $616,000,000 | $732,000,000 |
| Amortization Of Intangibles | $581,000,000 | $588,000,000 | $616,000,000 | $732,000,000 |
| Depreciation | $421,000,000 | $471,000,000 | $537,000,000 | $576,000,000 |
| Gain Loss On Sale Of Business | $0 | $-22,000,000 | $-41,000,000 | $10,000,000 |
| Net Income From Continuing Operations | $1,418,000,000 | $-1,959,000,000 | $-615,000,000 | $-2,499,000,000 |
| Income Tax Paid Supplemental Data | - | $471,000,000 | $298,000,000 | $543,000,000 |
| Gain Loss On Investment Securities | - | - | $-41,000,000 | $10,000,000 |
| Gain Loss On Sale Of PPE | - | - | - | $10,000,000 |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-07-03